Envision a world without HBV

Innovative therapies

Antios is developing transformative treatments for hepatitis B virus (HBV).

Learn more

HBV remains a formidable challenge

Even after decades of ongoing effort, the current standard of care is unable to provide a functional cure for HBV infection1

Our lead therapeutic candidate, ATI-2173, is the only active site polymerase inhibitor nucleotide (ASPIN) in development


Discover how our collaborative efforts are helping us achieve our goals

Antios has been exploring combination therapy with other complementary drug classes to shut down viral replication and take the first step toward a potential cure for hepatitis B.2,3

Learn more about our research in combination therapy for the treatment of HBV.

View clinical trial data

ASPIN MOA

ATI-2173 leverages a novel mechanism of action (MOA) to disrupt polymerase activity and shut down viral replication.1

Watch ASPIN MOA Video

Antios is currently developing ATI-1428 for
the treatment of HBV1

Antios was founded in 2018 with the goal of treating and curing HBV.

Learn more about Antios

Learn more about ATI-2173, the first step toward a cure for HBV.

Learn more about ATI-2173

ATI-2173 demonstrated efficacy and safety in phase 2 clinical trials.1

View clinical trial data

Latest News

References: 1. Data on file. Antios Therapeutics, Doylestown, PA. 2. Squires KE, Mayers DL, Bluemling GR, et al. ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens. Antimicrob Agents Chemother. 2020;64(9):e00836-20. 3. Mayers DL. ATI-2173: a novel active site polymerase inhibitor nucleotide (ASPIN). Presented at: Hep DART; December 5-9, 2021; Los Cabos, Mexico.

Improving lives through the treatment of HBV About our therapies